@Protalix_Bio

Protalix (NYSE: $PLX) is dedicated to developing and commercializing therapeutic proteins with clinically improved profiles, produced by our ProCellEx® system

protalix.com/
Joined May 2020
  • Tweets215
  • Following54
  • Followers4.9K
19Media
Join us on December 5th at 8:30 AM ET for a KOL Event with @Protalix_Bio, featuring Myrl D. Holida (Physician Assistant), on Fabry Disease and Protalix’s investigational drug PRX-102 (pegunigalsidase alfa). Register here: lifesci.events/ProtalixReg $PLX
1
2
We announced with our partner @Protalix_Bio topline results from the Phase III BALANCE clinical trial in #Fabrydisease. For details, see our press release: bit.ly/3vdO1Dv
3
1
10
Today is #RareDiseaseDay! Follow our video tutorial to join the #WeWearStripes initiative and show your support to all people living with a #raredisease. #ChiesiGlobalRareDiseases
1
3
1
16
Our Fireside Chat with $PLX is starting soon at 9AM ET today, 30JUN21! Webcast: us02web.zoom.us/j/8611349009… Dial-in: 346 248 7799 (Houston) Meeting ID: 861 1349 0096 #business #dowjones #forex #health #healthcare #investing #nasdaq #nyse #stockmarket #stocknews #stocks #trading
1
3
2
15
.@Protalix_Bio is focused on the development and commercialization of recombinant therapeutic proteins through its proprietary plant cell-based expression system, ProCellEx®. Join their #roundtable discussion on Wed, Oct. 28th at 10 AM ET. virtualinvestorco.com/protal… $PLX
2
FDA starts review of @Protalix_Bio and Chiesi’s long-acting Fabry disease therapy pegunigalsidase alfa, setting up a possible approval by 27 January bit.ly/30O54xX
3
Load more